U.S. Oligonucleotide Synthesis Market Is Set For Lucrative Growth To 2030

U.S. Oligonucleotide Synthesis Market Summary

The U.S. oligonucleotide synthesis market size was valued at USD 1.36 billion in 2023 and is anticipated to grow at a robust compound annual growth rate (CAGR) of 12.80% from 2024 to 2030. Growth is largely fueled by the increasing demand for synthetic DNA and RNA sequences across a wide range of applications, including molecular biology research, advanced diagnostics, and the development of innovative therapeutics. The market landscape is highly competitive, with a combination of well-established global leaders and emerging regional players striving to gain market share. Among the most prominent companies are Integrated DNA Technologies, Thermo Fisher Scientific, Eurofins Scientific, and Bio-Synthesis, Inc., which continue to hold a strong presence in the U.S. market through their innovative product portfolios and strategic initiatives.

These leading companies are recognized for providing comprehensive and high-quality oligonucleotide products and services tailored to meet diverse customer needs. To strengthen their market position, many players are pursuing collaborations, acquisitions, and partnerships aimed at expanding technological capabilities, scaling up production, and accessing untapped market segments. For instance, in February 2023, Fluor Corp., headquartered in Irving, Texas, was selected by Agilent Technologies, Inc. to enhance its oligonucleotide therapeutics manufacturing facility in Colorado, U.S., located just north of Denver. This project, valued at approximately USD 725 million, highlights the rising investments in large-scale oligonucleotide manufacturing capacity. Fluor will be responsible for delivering engineering and procurement services, reflecting the growing importance of infrastructure development in supporting therapeutic innovations.

Key Market Trends & Insights

• The services segment dominated the market with the largest share of 37.34% in 2023 and is projected to witness the fastest growth throughout the forecast period. This expansion is driven by the increasing complexity of genomic research and therapeutic applications, which require precise synthesis, purification, and customization of oligonucleotide sequences. Outsourcing to specialized service providers enables research organizations and companies to save time, reduce costs, and gain access to advanced expertise and technology platforms.
• Within product categories, the PCR primers segment held the largest revenue share of 22.33% in 2023. PCR primers are fundamental to polymerase chain reaction (PCR) technology, a widely used technique in laboratories for detecting and amplifying small amounts of DNA or RNA. Their application plays a vital role in the diagnosis of infectious diseases, including viral, bacterial, and parasitic infections. By enabling rapid and highly accurate pathogen detection, PCR primers support timely treatment interventions and significantly improve patient outcomes.
• In terms of end users, academic research institutes accounted for the largest market share of 43.16% in 2023. U.S. academic institutions are recognized as leaders in advancing genomic research and innovation, contributing significantly to the development of new approaches in gene editing, molecular diagnostics, and disease pathway analysis. Researchers in academia, motivated by both scientific curiosity and the goal of advancing knowledge, explore diverse areas of genomics and continue to contribute to the growing demand for oligonucleotide synthesis.
• Pharmaceutical and biotechnology companies are projected to record the fastest CAGR of 14.67% from 2024 to 2030. These companies are increasingly adopting precision medicine approaches, which focus on targeting specific genetic mutations, biomarkers, or molecular pathways associated with disease. The growing adoption of personalized therapeutics, coupled with rising investment in drug discovery and clinical research, is expected to drive substantial demand for oligonucleotide synthesis within the pharmaceutical and biotechnology sector.

Order a free sample PDF of the U.S. Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 1.36 billion
• 2030 Projected Market Size: USD 3.09 billion
• CAGR (2024 - 2030): 12.80%

Key Companies & Market Share Insights

The market players operating in the U.S. oligonucleotide synthesis industry are undertaking product approvals to expand their product presence and enhance accessibility across various geographical regions. Expansion serves as a strategy to bolster production and research purposes. Moreover, numerous market entities are engaging in acquisitions of smaller firms to improve their market position. This approach enables companies to enhance capabilities, broaden product offerings, and develop new competencies.

Key Players

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Danaher Corporation
• Dharmacon Inc.
• Agilent Technologies
• Bio-synthesis
• LGC Biosearch Technologies
• Twist Bioscience
• TriLink BioTechnologies
• Genscript

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. oligonucleotide synthesis market is witnessing rapid expansion, driven by the growing need for synthetic DNA and RNA sequences in both research and clinical applications. Academic institutions currently hold the largest share, reflecting their leading role in scientific innovation, while pharmaceutical and biotechnology companies are poised for the fastest growth as precision medicine becomes more widespread. With increasing investment in infrastructure, services, and advanced technologies, the market is expected to remain highly competitive and innovation-driven. Strong demand for outsourcing, advanced PCR primers, and customized solutions will continue to accelerate growth, positioning the market as a key contributor to future genomic and therapeutic advancements.